Rafferty Asset Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-30,280
| Closed | -$617K | – | 1108 |
|
|
2025
Q4 | $617K | Sell |
30,280
-13,786
| -31% | -$242K | ﹤0.01% | 880 |
|
|
2025
Q3 | $697K | Sell |
44,066
-10,228
| -19% | -$151K | ﹤0.01% | 851 |
|
|
2025
Q2 | $725K | Sell |
54,294
-1,038
| -2% | -$14K | ﹤0.01% | 812 |
|
|
2025
Q1 | $564K | Buy |
55,332
+9,531
| +21% | +$111K | ﹤0.01% | 840 |
|
|
2024
Q4 | $725K | Buy |
45,801
+4,689
| +11% | +$244K | ﹤0.01% | 850 |
|
|
2024
Q3 | $2.39M | Sell |
41,112
-16,443
| -29% | -$812K | 0.01% | 585 |
|
|
2024
Q2 | $2.63M | Sell |
57,555
-61,956
| -52% | -$3.33M | 0.01% | 568 |
|
|
2024
Q1 | $7.91M | Buy |
119,511
+54,230
| +83% | +$3.22M | 0.03% | 350 |
|
|
2023
Q4 | $2.6M | Buy |
65,281
+7,092
| +12% | +$222K | 0.01% | 607 |
|
|
2023
Q3 | $1.86M | Sell |
58,189
-12,067
| -17% | -$450K | 0.01% | 631 |
|
|
2023
Q2 | $2.82M | Buy |
70,256
+7,225
| +11% | +$317K | 0.02% | 547 |
|
|
2023
Q1 | $2.69M | Sell |
63,031
-2,785
| -4% | -$141K | 0.02% | 528 |
|
|
2022
Q4 | $3.16M | Buy |
65,816
+8,519
| +15% | +$398K | 0.03% | 473 |
|
|
2022
Q3 | $2.16M | Buy |
57,297
+19,936
| +53% | +$691K | 0.02% | 491 |
|
|
2022
Q2 | $1.03M | Buy |
37,361
+3,092
| +9% | +$136K | 0.01% | 629 |
|
|
2022
Q1 | $1.86M | Sell |
34,269
-2,536
| -7% | -$130K | 0.01% | 628 |
|
|
2021
Q4 | $2.15M | Buy |
36,805
+12,459
| +51% | +$621K | 0.01% | 633 |
|
|
2021
Q3 | $963K | Sell |
24,346
-1,000
| -4% | -$35.6K | 0.01% | 841 |
|
|
2021
Q2 | $1.08M | Sell |
25,346
-8,685
| -26% | -$470K | 0.01% | 861 |
|
|
2021
Q1 | $2.1M | Buy |
34,031
+30,951
| +1,005% | +$1.96M | 0.01% | 611 |
|
|
2020
Q4 | $217K | Buy |
+3,080
| New | +$194K | ﹤0.01% | 968 |
|
Other funds holding KROS
NCM
VCM
O
VPM
MAP